Bladder Cancer Clinical Trial
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health.
Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or urethra.
Locally advanced unresectable or metastatic stage disease
Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing.
At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy.
Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the start of data collection
Radiographically documented and measurable disease progression immediately before index date
Any concurrent malignant neoplasm requiring systemic therapy during the study window
Enrollment in a therapeutic clinical trial and received non-standard of care treatment within 1 year prior to the index date
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Orange California, 92868, United States More Info
San Francisco California, 94158, United States More Info
Aurora Colorado, 80045, United States More Info
Sioux Falls South Dakota, 57105, United States More Info
Rouen , 76000, France More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.